Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: Short-term follow-up [11]

Eye

Volumn 21, Issue 4, 2007, Pages 566-567

  Amselem, L ^a   Cervera, E ^a   Diaz Llopis M ^a   Montero, J ^a   Garcia Pous, M ^a   Udaondo, P ^a   Garcia Delpech S ^a   Salom, D ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; NAVELBINE; OXALIPLATIN;

ADULT; B SCAN; BONE METASTASIS; BREAST CARCINOMA; CANCER STAGING; CASE REPORT; CHOROID TUMOR; CLINICAL FEATURE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LETTER; LUNG METASTASIS; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA FOVEA; SUBRETINAL FLUID; TUMOR VOLUME; VISUAL ACUITY;

EID: 34147135136     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702647     Document Type: Letter

References (4)

1. Shields CL, Shields JA, Gross N, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology 1997; 104: 1265-1276.
2. Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006; 20(3): 193-195.
3. Senior K. Combination treatment improves breast cancer survival. Lancet Oncol 2006; 7(5): 370.
4. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26(3): 257-261.